(4-hydroxy-phenyl)-carbamic acid pentyl ester | 83264-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-hydroxy-phenyl)-carbamic acid pentyl ester
• 英文别名: (4-Hydroxy-phenyl)-carbamidsaeure-pentylester；pentyl N-(4-hydroxyphenyl)carbamate
• CAS: 83264-10-2
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: JADJOGIPYORDQZ-UHFFFAOYSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  317.1±25.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-hydroxy-phenyl)-carbamic acid pentyl ester 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 24.0h， 生成 [4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-carbamic acid pentyl ester
  参考文献：
  名称：

  Synthesis and structure-activity relationships of new β-adrenoreceptor antagonists. Evidence for the electrostatic requirements for β-adrenoreceptor antagonists

  摘要：

  A series of mono- and disubstituted phenoxypropanolamines, structurally related to practolol and acebutolol, has been synthesized and tested for beta-adrenoreceptor blocking activity. Structure-activity relationships are discussed. The reasons for the lack of activity of compounds 3n and 4n have also been examined. The results suggest that the negative electrostatic potential above the phenyl ring of phenoxypropanolamines is essential for binding activity and point to the presence of an electropositive residue in the beta-adrenoreceptor binding site.

  DOI：

  10.1016/0223-5234(91)90127-9
• 作为产物：
  描述：

  氯甲酸正戊酯 、 对氨基苯酚 以 乙醚 为溶剂， 反应 1.0h， 生成 (4-hydroxy-phenyl)-carbamic acid pentyl ester
  参考文献：
  名称：

  Synthesis and structure-activity relationships of new β-adrenoreceptor antagonists. Evidence for the electrostatic requirements for β-adrenoreceptor antagonists

  摘要：

  A series of mono- and disubstituted phenoxypropanolamines, structurally related to practolol and acebutolol, has been synthesized and tested for beta-adrenoreceptor blocking activity. Structure-activity relationships are discussed. The reasons for the lack of activity of compounds 3n and 4n have also been examined. The results suggest that the negative electrostatic potential above the phenyl ring of phenoxypropanolamines is essential for binding activity and point to the presence of an electropositive residue in the beta-adrenoreceptor binding site.

  DOI：

  10.1016/0223-5234(91)90127-9

文献信息

• Reversing baldness through follicle regeneration
  申请人：Postrel Richard

  公开号：US11331300B2

  公开（公告）日：2022-05-17

  This invention reverses male pattern baldness by shocking dormant hair follicles out of their androgen induced hibernation phase back to the active hair-growing anagenic phase. The invention integrates two functions: 1) It blocks synthesis of compounds holding the follicles in the telogenic/hibernating phase and 2) It stimulates synthesis of compounds animating the hair-growing/anagenic phase in the follicular activity cycle. One preferred embodiment comprises an enzyme inhibitor blocking the conversion of testosterone to dihydrotestosterone (DHT), a flavonoid simultaneously increasing synthesis of prostaglandins alternative to prostaglandin D2, and a selected cannabinoid compound stimulating restore the hair follicle to its normal growth cycle. This novel trimodal therapy restores the hair follicles to their normal cycling processes and maintains these restorative properties so long as this rebalance in maintained.

  本发明通过将休眠毛囊从雄性激素诱导的冬眠期震回到活跃的头发生长期，从而逆转男性型秃发。本发明集成了两种功能：1）阻止使毛囊处于休止期/冬眠期的化合物的合成；2）刺激毛囊活动周期中使毛发生长期/新生期活跃的化合物的合成。一个优选的实施方案包括：一种酶抑制剂，可阻止睾酮向双氢睾酮（DHT）的转化；一种类黄酮，可同时增加前列腺素 D2 替代物的合成；以及一种精选的大麻素化合物，可刺激毛囊恢复正常的生长周期。这种新颖的三联疗法能使毛囊恢复正常的循环过程，只要保持这种恢复平衡，就能保持这些恢复特性。
• Chabrier et al., Bulletin de la Societe Chimique de France, 1955, p. 1353,1358
  作者：Chabrier et al.

  DOI：——

  日期：——
• CSOLLEI, J.;BOROVANSKY, A.;BENES, L.;BEDEROVA, E.;SVEC, P., CS. FARM., 1982, 31, N 6, 229-235
  作者：CSOLLEI, J.、BOROVANSKY, A.、BENES, L.、BEDEROVA, E.、SVEC, P.

  DOI：——

  日期：——
• QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES
  申请人：Postrel Richard

  公开号：US20190029993A1

  公开（公告）日：2019-01-31

  This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.
• HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING
  申请人：Postrel Richard

  公开号：US20190030044A1

  公开（公告）日：2019-01-31

  This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as a human continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.